



Clinical Trials

Risk and Insurance Guide



Contents

Overview..... 3

Our support..... 4

Insurance 5

Clinical trials documentation 6

External expert reviews 7

Risk management..... 8


Frequently asked questions..... 13

Resources 15

© State of Victoria 2025



You are free to re-use this work under a Creative Commons Attribution 4.0 licence, provided you credit the State of Victoria (Victorian Managed Insurance Authority) as the author, indicate if changes were made and comply with the other licence terms. The licence does not apply to any branding, including Government logos.

VMIA is the Victorian Government's insurer and risk adviser	Level 10 South 161 Collins Street Melbourne VIC 3000	P (03) 9270 6900 E contact@vmia.vic.gov.au ABN 39 682 497 841	vmia.vic.gov.au © Victorian Managed Insurance Authority	
--	--	--	---	---

Victorian Managed Insurance Authority (VMIA) acknowledges the Traditional Custodians of the land on which we do business, and we pay our respects to Elders past and present. We acknowledge the important contribution that Aboriginal and Torres Strait Islander peoples make in creating a thriving Victoria.

Overview

Clinical trials play a very important role in the Australian health sector, providing significant benefits to both the Australian community and the economy.

Clinical trials are essential for evaluating the effectiveness and safety of drugs, devices, services and interventions to help prevent, detect or treat illness and disease. It is through the research done in clinical trials that patients gain access to better treatments sooner. Clinical trials also bring hundreds of millions of dollars each year into the Australian economy.

Australia is a leader in the governance of clinical trials, and we continue to be competitive as a clinical trial host country. The speed and the efficiency with which proposed clinical trials are considered and approved ensures Australia continues to lead the way for clinical trials.

We support Victoria's efforts to maintain the highest standards of clinical trial and research governance and efficient approval processes for clinical trials.

The Clinical Trials Risk and Insurance Guide has been developed in consultation with the Victorian Department of Health to ensure it is consistent with the Victorian Government's policies, current multi-state agreements and the overall governance framework for clinical trials in Victoria.

Using this guide

This guide provides a practical explanation of VMIA's role in supporting clinical trials in Victoria.

It provides answers to frequently asked insurance and risk questions and directs you to additional resources.

Our support

Our purpose is to build a confident, resilient Victoria through world leading harm prevention and recovery. We form strategic partnerships with government departments and agencies to identify and mitigate harm and manage State significant risks. We understand your business and are experts in risk and insurance. We exist to support you to manage your risk and prevent harm to the Victorian Community.

Our risk advisers will work with you to meet your risk and insurance needs as well as assist you with embedding enterprise and insurable risk management into your organisational practices.

Our work is about:

- Education
Building the skills and capabilities of your team to better respond to risks.
- Advice
Providing expert advice and consulting services to assist you in tackling your issues, guiding action and decision making.
- Insight
Helping you turn information into knowledge, to know what's important and guide your action.
- Learn
Reflecting on what's gone wrong to make changes for the future.

VMIA is here to support public health sector agencies involved in clinical trials and health and medical research.

Insurance

This section outlines the insurance policies which are available to public health sector agencies to help protect them from the financial risk if something going wrong arising from clinical trials and health and medical research.

VMIA provides insurance cover for key risks associated with clinical trials. These policies include a definition of 'clinical trials and health and medical research' and the definition of 'health care services' includes 'clinical trials and health and medical research'.

Medical Indemnity

Patient care can be complex and sometimes results in errors or omissions. As a health service provider, you may be held liable for personal injuries, resulting in costly settlements and legal expenses. Medical indemnity insurance covers claims seeking compensation for personal injuries, which may arise from the provision of health care services.

Medical Indemnity

<https://www.vmia.vic.gov.au/insurance/policies-and-cover>

Combined Liability

Coverage for each of these policies is specified in two sections of the policy, Section 1 - Public and Products Liability and Section 2 – Professional Indemnity.

Combined Liability – Section 1 Cover – Public and Products Liability

During the course of conducting business activities, you may receive a claim for personal injury or property damage from a client, member of the public or another organisation. Defending these claims, even if you are not at fault, can result in costly legal expenses. Public and products liability insurance covers legal liabilities arising from business activities that result in personal injury or property damage to third parties. To obtain full policy wordings, please refer to the following links on VMIA's website.

Combined Liability – Section 2 Cover – Professional Indemnity

If your organisation provides advice, specialised knowledge or expertise of any kind, it may be held liable for an error or omission. Professional indemnity provides cover for an alleged breach of professional duties.

Combined Liability

<https://www.vmia.vic.gov.au/insurance/policies-and-cover>

Clinical trials documentation

This section outlines the various types of clinical trials sponsorship agreements available. These agreements aim to ensure that obligations for both sponsors and institutions are fair and reasonable and provide a degree of certainty of application in the commercial clinical trial environment.

The sponsor of a clinical trial is the company, institution, organisation, body or individual that takes responsibility for the funding and conduct of the clinical trial. The type of sponsorship agreement you enter will determine the agreement and indemnity forms you will need to complete.

Type of Sponsorship	Research Agreement Form	Indemnity Forms
Commercial Trials		
Commercially Sponsored Trial of a Pharmaceutical	Clinical Trial Research Agreement – Standard Form on Medicines Australia website Clinical Trial Research Agreement Phase 4 Clinical Trial (Medicines) on Medicines Australia website	Standard Indemnity Form on Medicines Australia website
Commercially Sponsored Trial of a Device	Clinical Investigation Research Agreement – Standard Form on Medical Technology Association of Australia website	Standard Indemnity Form for a Clinical Investigation on Medical Technology Association of Australia website
Contract Research Organisation (CRO) acting as the local Sponsor	Clinical Trial Research Agreement – CRO specific on Medicines Australia website	Standard Indemnity Form on Medicines Australia website
Research Studies		
Collaborative or Cooperative Research Group (CRG)	Clinical Trial Research Agreement – CRG specific on Medicines Australia website	Both the CRG and IIS standard agreements have the same general ‘liability and insurance’ clause. The intent of the clause is that each party is liable for its acts and omissions in relation to the conduct of the study.
Investigator Initiated Study (IIS)	Clinical Trial Research Agreement - IIS specific There is currently no IIS specific Clinical Trials Research Agreement template available online	

External expert reviews

This section outlines the requirements to ensure that external expert reviews are adequately protected by insurance.

An external expert reviewer is appointed to provide an independent review on the appropriateness of the clinical trials protocols and the risks and benefits to participants. The reviewer is not involved in the research and can be either an employee of a VMIA client or contracted to provide the service. There are two types of reviewer:

1. An employee of a VMIA insured agency

The expert reviewer is covered under the VMIA Public Health Program, subject to any relevant policy exclusions, terms and/or conditions.

2. Not an employee of a VMIA insured agency

You should ensure that the reviewer provides you with a Certificate of Currency for a Professional Indemnity insurance policy covering the reviewer for the provision of these services.

If the reviewer doesn't have a current professional indemnity insurance policy or can't provide confirmation that their professional indemnity insurance policy covers them for the review, you must complete a [Details of Independent Review](#) form and submit to VMIA via email at contact@vmia.vic.gov.au

Refer to the template [Coverage for Independent Reviewer](#)

Risk management

This section highlights some concepts associated with managing research risk and suggests VMIA guides that can help with this topic.

Effective risk management is an integral and essential part of ensuring participant safety in clinical trials. It supports decision makers in understanding both the benefits of conducting a clinical trial as well as the clinical risks and/or associated hazards.

Find out how risk thinking and management techniques can help you make better decisions in the context of your clinical research efforts by reviewing these selected guides.

What is risk?

Risk isn't just about thinking "what might go wrong?", it's about reflecting on your research objectives and your pursuit of new knowledge. Read our "What is risk" guide for more.

How can risk management add and protect value?

Research is a deliberate exploration of the unknown and unpredictable. It's important to view the act of managing risk as an enabler of this pursuit. Risk management adds value but doesn't stifle innovation and creativity.

Victorian Government expectations

Public sector agencies are required to maintain a risk management framework that aligns with the:

- Principles and practices of the Australian/New Zealand Risk Management Standard (AS/NZS ISO 31000:2018);
- Victorian Government Risk Management Framework; and
- legislation such as Financial Management Act 1994

Risk management should be informed by and consistent with the requirements of other agreements, legislation, regulations and guidelines under you conduct clinical trials.

Risk management includes the structures, processes and activities undertaken to ensure that:

- adequate oversight, reporting, monitoring and assurance occurs
- risks are identified, assessed and action is taken
- controls are identified, assessed for effectiveness and sufficient investment occurs in ensuring the controls mitigate the risk
- people have the right capability and skills to manage risk.

Proactively thinking about risk is a discipline and mind-set which will:

- increase the chance of achieving objectives and successfully executing strategies and plans
- improve culture
- provide confidence to Government and the community
- promote the efficient resource allocation
- address negative perceptions and impact on reputation
- empower people to make decisions with confidence
- determine how much risk can be taken and tolerated
- inspire others to follow examples and work collaboratively.

A risk management framework is the term used to describe the totality of all processes, procedures, documents, policies, resources, governance, and arrangements an agency has in place that contribute to risk management. A framework is essential to ensure there is an agreed approach to manage risk. It is required as part of overall governance arrangements and will also complement and support other frameworks.

A risk management strategy (may be referred to as a risk plan or risk policy) outlines and describes the key elements of the risk management framework. It specifies the approach, the management components and resources to be applied to the management of risk. It incorporates key activities designed to achieve these objectives and the plan to build risk management capability and maturity.


What process should I follow when designing and managing research?

The risk management process is a core component of the risk management framework.

The essential component of this process is risk assessment which is outlined in this guide describes the design process: <https://www.vmia.vic.gov.au/tools-and-insights/practical-guidance-for-managing-risk/designing-processes>

Having a documented risk management process is important as it will outline the steps to:

- establish the context
- understand what is uncertain and any potential effects
- identify and assess what could happen
- make a decision about what needs to occur.



AS/NZS ISO 31000:2018

Risk management process (continued)

Communicate and consult	Actively engage with stakeholders throughout each step of the process.
Establish the scope, context and criteria	This involves an examination of the external and internal context i.e. consider the organisation's culture and environment both of which influence how risks are managed
Identify risks <i>What could happen?</i>	<p>To identify risks, consider how uncertainty in our external and internal context could give rise to risk and therefore impact the achievement of objectives. Essentially, what's the event that happened, could affect your objectives?</p> <p>There are many sources to draw from including business plans, incidents, feedback, legislation, new trials and research.</p>
Analyse risks <i>What does that mean for us?</i>	<p>What's currently in place (controls), to manage the risk?</p> <p>Taking into account the effectiveness of the current controls, what is the likelihood of the event happening and the consequences should it occur?</p> <p>Use your organisation's 'risk rating' matrix to calculate the level of risk.</p>
Evaluate risks <i>What are our priorities?</i>	<p>Use the 'risk rating' to inform decision making about whether the risk is acceptable or not.</p> <p>Consider the degree of control possible for that risk, and the costs and benefits associated with treating it.</p> <p>Prioritise unacceptable risks and communicate the rationale for your decisions.</p>
Treat risks <i>What are we going to do to address the risk?</i>	<p>Consider treatment options and action plans for controlling risks. Options include:</p> <ul style="list-style-type: none"> • Avoiding the risk by ceasing to perform the activity, function or service. • Reducing the likelihood and/or consequence of the risk by 'modifying' work practices, systems and processes. • Removing the risk source • Sharing the risk with another party, such as an insurer or contractor or in a partnership. • Retaining the risk can be an informed decision.
Monitor and review	Monitor and review the effectiveness of actions taken to address the risk.
Record and report	To provide assurance to stakeholders and demonstrate good governance, the risk management process and its outcomes should be documented and reported through appropriate mechanisms.

Research risks and risk categories

Our guides have some suggestions on risk categories to help you think about threats and opportunities. You can check out these suggestions on our Risk Management Tools webpage [Risk management tools | Victorian Managed Insurance Authority \(vmia.vic.gov.au\)](https://vmia.vic.gov.au/risk-management-tools)

In addition to these general suggestions, you might want to consider the following categories in the context of clinical trials:

Financial	<ul style="list-style-type: none"> Liquidity – failure to secure timely/ adequate funding Fraud – misappropriation of funds Over reliance on primary funding source
Infrastructure	<ul style="list-style-type: none"> Failure of key utilities and infrastructure– e.g. electricity, cooling IT and/or communications outage Theft
Commercial	<ul style="list-style-type: none"> Breach of contract Failure to protect intellectual property Breach of intellectual property or patent Breach of privacy or confidentiality Coercion of research participants Serious research misconduct Publication of inaccurate or incomplete information
Operational	<ul style="list-style-type: none"> Poor research outcomes Serious errors in research data analysis Damage/loss of key research specimens Lost, damaged or incomplete research records Inadequate consent of research participants Inappropriate disposal of hazardous waste Inappropriate storage or use of hazardous materials Failure to procure the right supplies within budget Security breach of information systems
Safety	<ul style="list-style-type: none"> Laboratory hazards – serious staff injury Failure to identify and treat adverse clinical outcomes Security threat to personnel Staff exposure to genetically modified organisms
Human Resources	<ul style="list-style-type: none"> Failure to recruit and retain staff to critical roles Failure to verify credentials and scope of practice Breach of employment contract Industrial dispute
Governance	<ul style="list-style-type: none"> Failure to comply with regulatory requirements Undeclared conflicts of interest Disruption to business continuity Ineffective project management Breakdown of key internal or external relationships Approval of a project with unjustified ‘net research risk’
Strategic	<ul style="list-style-type: none"> Significant change in government research policy Significant change in regulatory requirements Financial crisis – reduced opportunities for fund raising

Operational Risk Example (for demonstration purposes only)

– Serious errors in research data analysis¹

Description of risk

The conclusion drawn from a published research project can alter clinical practice or public health policy. It's therefore important that every project is conducted and analysed with care. A serious error in the analysis of research data may lead to retraction of a published article which is likely to have considerable cost implications to the organisation as well as substantial legal liability, not to mention putting patients at risk of not receiving the best possible treatment.

Likelihood of occurrence

Analysis of large datasets requires considerable expertise with modern data- management packages. This expertise is only obtained only through extensive experience under expert supervision. Modern statistical packages allow advanced analysis to be undertaken by junior researchers but at a high risk of inappropriate application.

Serious errors are more likely when the analysis of data is delegated to unsupervised junior researchers or research students. Mistakes are easy to make and are more often difficult to detect because the intuitive feeling for data is less than with small paper-based datasets.

Likely consequences

If the study has been published it may require formal withdrawal at substantial cost to the reputation of the research team. If the study has influenced clinical practice, patients may be treated with ineffective interventions or not receive effective therapy. Falsified data may lead to a breach of contract with an external research sponsor and liability for damages. The study may have to be repeated at a heavy cost to the organisation.

Risk treatment options to the occurrence of this risk

All research data should be analysed under the direction of (or in collaboration with) a biostatistician. All research projects should involve a member of the biostatistics unit and an appropriate allocation of research funds for statistical analysis should be included in all research grants.

No significant original result should be published without the senior researcher being able to certify that a statistician has undertaken the analysis (or checked the analysis). The only exception is when a small project involving a statistician has reported (to the principal investigator) sufficient confidence in the statistical expertise to the researcher to make direct supervision unnecessary.

¹ The above operational risk example was provided courtesy of the [Monash University School of Public Health and Preventive Medicine](#).

Frequently asked questions

When should you notify VMIA of an incident?

Notify us as soon as you are aware of the incident (and have stabilised the participant). Submit a copy of the Suspected Unexpected Serious Adverse Reaction Form to VMIA, at the same time it is submitted to the responsible Human Research Ethics Committee for the clinical trial.

What must you submit to VMIA?

- A copy of the Suspected Unexpected Serious Adverse Reaction Form that is completed for the responsible Human Research Ethics Committee for the clinical trial.
- Additional participant specific details such as name, date of birth, trial and/or identification number. The participant's identity is required in the event that a claim arises.
- You are only required to report in respect of your own participants.

What types of events do not require Suspected Unexpected Serious Adverse Reaction notification?

- Temporary and mild deterioration or change in a participant's condition
- Minor or short term events that have resolved
- Known adverse events/side effects of the trial drug
- Clearly identified events unrelated to the trial
- Events that have occurred to trial participants located overseas.

How do you notify VMIA?

The form should be submitted to VMIA by email at miclaims@vmia.vic.gov.au

Who is covered for clinical trials?

Medical Indemnity and Combined Liability insurance policies explicitly state the scope of insurance cover provided in relation to clinical trials and health and medical research conducted in Victoria. If you are a VMIA insured agency then you are covered for clinical trials.

Is approval from VMIA required for a clinical trial?

There is no requirement to seek approval from us for any aspect of a clinical trial.

When should VMIA be contacted regarding a clinical trial?

- To report a Suspected Unexpected Serious Adverse Reaction, or
- To request indemnity for an External Expert Reviewer in respect to a First Time In Human study.

Does VMIA have minimum insurance requirements for commercially sponsored clinical trials?

We do not set or recommend minimum insurance requirements for commercially sponsored clinical trials.

Do you need to provide VMIA insurance certificates of currency for commercially sponsored clinical trials?

You are not required to provide insurance certificates for commercially sponsored clinical trials.

Does the VMIA insurance program provide cover for international trials being conducted by a VMIA insured agency?

Not all international clinical trials are covered by the VMIA insurance program. The medical indemnity policy only provides cover for clinical trials conducted in Australia, Papua New Guinea and New Zealand. If your organisation is involved in clinical trials outside of these jurisdictions then please contact VMIA to discuss your insurance requirements.

Does the sponsor of a clinical trial in Australia have to be an Australian entity?

International pharmaceutical and biotechnology companies and groups of researchers can conduct clinical trials in Australia. Trials must be sponsored by an Australian entity. The entity can be an individual, company, institution or organisation that takes responsibility for the initiation, management, provision of insurance and indemnity, and/or financing of a clinical trial.

Refer to: [Industry and sponsors | Australian Clinical Trials](#)

What level of insurance coverage should a commercial sponsor provide?

We recommend that the commercial sponsors should provide insurance coverage for a minimum of AUD \$10 million.

What clinical trial research agreement form should you use?

Refer to clinical trials documentation section - page 6.

Medicines Australia is the reference source for clinical trials research agreements and we recommend you refer to their website for advice on agreements.

Can clinical trial research agreements be amended?

Medicines Australia is the reference source for clinical trials research agreements, and we recommend you refer to their website for advice on amendments to agreements.

Refer to: <https://www.medicinesaustralia.com.au/policy/clinical-trials/>

Resources

National Health and Medical Research Council

<https://www.nhmrc.gov.au/research-policy/clinical-trial-reform>

Australian Commission on Safety and Quality in Health Care

[National Clinical Trials Governance Framework | Australian Commission on Safety and Quality in Health Care](#)

Australian Clinical Trials

<http://www.australianclinicaltrials.gov.au/researchers>

Therapeutic Goods Administration

<http://www.tga.gov.au/>

Medical Technology Association of Australia

<https://www.mtaa.org.au/clinical-trials-australia>

Medicines Australia

<https://medicinesaustralia.com.au/policy/clinical-trials/>

Clinical Trial Research (Department of Health Victoria)

<https://www.health.vic.gov.au/about/medical-research>

Victorian Managed Insurance Authority

<https://www.vmia.vic.gov.au/tools-and-insights/practical-guidance-for-managing-risk>

International Standards Organisation

[International Standard ISO 31000 Second Edition 2018-02](#)

For further guidance on risk management, please refer to [VMIA's website](#).

[VMIA's Risk Guides](#) were developed to help Victorian government agencies use risk management to support decision making and address the requirements of the Victorian Government Risk Management Framework.